SCHEMBL16933882

SCHEMBL16933882

COCCOCc1ccc(-c2ccc(C(C)(C)NC(=O)N3CCN4CCC3CC4)cc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 1/20 0.35
▸ CHRNA7 P36544 4/20 0.34
▸ HTR3A P46098 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ SLC6A5 Q9Y345 1/20 0.33
▸ GBA1 P04062 1/20 0.33
▸ UGCG Q16739 1/20 0.33
▸ GBA2 Q9HCG7 1/20 0.33
▸ DRD2 P14416 1/20 0.33
▸ DRD4 P21917 1/20 0.33
▸ DRD3 P35462 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16933694 0.86 CHRNA7 (0.40) HRH3CHRNA7UGCG
SCHEMBL16933550 0.83 CHRNA7 (0.39) HRH3CHRNA7
SCHEMBL16933688 0.81 MMP2 (0.41) HRH3CHRNA7HTR3A
SCHEMBL29400598 0.80 NTMT1 (0.45) UGCG
SCHEMBL16933668 0.79 CHRNA7 (0.37) HRH3CHRNA7HTR3A
SCHEMBL15578038 0.77 NTMT1 (0.53) UGCG
SCHEMBL15579362 0.77 HRH3 (0.33) HRH3POLBSLC6A5GBA1UGCG
SCHEMBL15578254 0.77 PTPN2 (0.42) —
SCHEMBL16933614 0.77 UGCG (0.32) CHRNA7HTR3AUGCG
SCHEMBL15579379 0.76 HRH3 (0.33) HRH3POLBSLC6A5GBA1UGCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026749-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2025-01-23 — — US disclosed
US-12060349-B2 Glucosylceramide synthase inhibitors GENZYME CORPORATION (US) 2024-08-13 — — US disclosed
EP-4098654-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS Genzyme Corporation (US) 2022-12-07 — — EP disclosed
CN-114533729-A Glucosylceramide synthase inhibitors 建新公司 2022-05-27 — — CN disclosed
US-20220073508-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2022-03-10 — — US disclosed
EP-2895484-B1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORP (US) 2022-02-23 — — EP disclosed
CN-108864076-B Glucosylceramide synthase inhibitors 建新公司 2022-02-11 — — CN disclosed
US-11008316-B2 Glucosylceramide synthase inhibitors GENZYME CORPORATION (US) 2021-05-18 — — US disclosed
US-20180065957-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2018-03-08 — — US disclosed
US-20150210681-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2015-07-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210681-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA HRH3 3525/4885CHRNA7 4631/4885HTR3A 4754/4885
US-20180065957-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA HRH3 3525/4885CHRNA7 4631/4885HTR3A 4754/4885
US-11008316-B2 Glucosylceramide synthase inhibitors GBA1, GBA2, GAA HRH3 3913/4885CHRNA7 4652/4885HTR3A 4811/4885
US-12060349-B2 Glucosylceramide synthase inhibitors GBA1, GBA2, GALC HRH3 4106/4885CHRNA7 4254/4885HTR3A 4800/4885
US-20250026749-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA HRH3 3525/4885CHRNA7 4631/4885HTR3A 4754/4885
US-20220073508-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA HRH3 3525/4885CHRNA7 4631/4885HTR3A 4754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback